Capecitabine
Agitation in Dementia
Benuvia Therapeutics Inc.Small moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Agitation in Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hmscs Bernard (Barry) Baumel | Phase 2 | CCC |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →